Implications of nanoscale based drug delivery systems in delivery and targeting tubulin binding agent, noscapine in cancer cells

Current Drug Metabolism

Volumn 13, Issue 10, 2012, Pages 1476-1483

  Chandra, Ramesh ^a   Madan, Jitender ^a   Singh, Prashant ^a   Chandra, Ankush ^a,c   Kumar, Pradeep ^a   Tomar, Vartika ^a   Dass, Sujata K ^b  

^a UNIVERSITY OF DELHI   (India)

^b UNIVERSITY OF DELHI   (India)

^c BOSTON UNIVERSITY   (United States)

Author keywords

9 Bromonoscapine; Cancer; Drug delivery; Noscapine; Pharmacokinetic

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; ALBUMIN; CISPLATIN; COLCHICINE; CYCLODEXTRIN; DOXORUBICIN; GELATIN; HYPOXIA INDUCIBLE FACTOR 1; LAROMUSTINE; MACROGOL; NANOPARTICLE; NOSCAPINE; SUPERPARAMAGNETIC IRON OXIDE; TAXANE DERIVATIVE; TUBULIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CELL CYCLE; CELL PROLIFERATION; DAUGHTER CELL; DIAGNOSTIC IMAGING; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TARGETING; HUMAN; MOLECULAR WEIGHT; NANOTECHNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PLASMA HALF LIFE; PROSTATE CANCER; SCANNING ELECTRON MICROSCOPY; SOLID TUMOR; TRANSMISSION ELECTRON MICROSCOPY; TRIPLE NEGATIVE BREAST CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; CYCLODEXTRINS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NEOPLASMS; NOSCAPINE; SERUM ALBUMIN; TUBULIN;

EID: 84870434926     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012803762756     Document Type: Article

References (50)

1. Landen, J.W.; Lang, R.; McMahon, S.J.; Rusan, N.M.; Yvon, A.M.; Adams, A.W.; Sorcinelli, M.D.; Campbell, R.; Bonaccorsi, P.; Ansel, J.C.; Archer, D.R.; Wadsworth, P.; Armstrong, C.A.; Joshi, H.C. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res., 2002, 62, 4109-4114.
2. Zhou, J.; Gupta, K.; Aggarwal, S.; Aneja, R.; Chandra, R.; Panda, D.; Joshi, H.C. Brominated derivatives of noscapine are potent microtubule- interfering agents that perturb mitosis and inhibit cell proliferation. Mol. Pharmacol., 2003, 63, 799-807.
3. Aneja, R.; Vangapandu, S.N.; Lopus, M.; Chandra, R.; Panda, D.; Joshi, H.C. Development of a novel nitro-derivative of noscapine for the potential treatment of drug resistant ovarian cancer and Tcell lymphoma. Mol. Pharmacol., 2006, 69, 1801-1809.
4. Aneja, R.; Zhou, J.; Zhou, B.; Chandra, R.; Joshi, H.C. Treatment of harmone-refractory breast cancer: apoptosis and regression of human tumors implanted in mice. Mol. Cancer Ther., 2006, 5, 2366-2377.
5. Mahmoudian, M.; Mehrpour, M.; Benaissa, F.; Siadatpour, Z. A preliminary report on the application of noscapine in the treatment of stroke. Eur. J. Clin. Pharmacol., 2003, 59, 579-581.
6. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod., 2007, 70, 461-477.
7. Butler, M.S. Natural products to drugs: natural product-derived compounds in clinical trials. Nat. Prod. Rep., 2008, 25, 475-516.
8. Madan, J.; Dhiman, N.; Parmar, V.K.; Sardana, S.; Bharatam, P.V.; Aneja, R.; Chandra, R.; Katyal, A. Inclusion complexes of noscapine in beta-cyclodextrin offer better solubility and improved pharmacokinetics. Cancer Chemother. Pharmacol., 2010, 65, 537-548.
9. Madan, J.; Dhiman, N.; Sardana, S.; Aneja, R.; Chandra, R.; Katyal, A. Long-circulating poly(ethylene glycol)-grafted gelatin nanoparticles customized for intracellular delivery of noscapine: preparation, in-vitro characterization, structure elucidation, pharmacokinetics, and cytotoxicity analyses. Anticancer Drugs, 2011, 22, 543-555.
10. Abdalla, O.M.; Aneja, R.; Dean, D.; Rangai, V.; Russell, A.; Jaynes, J.; Yates, C.; Turner, T. Synthesis and Characterization of noscapine loaded magnetic Polymeric nanoparticles. J. Magnet. Magnetic Mater., 2010, 322, 190-196.
11. Stanton, R.A.; Gernert, K.M.; Nettles, J.H.; Aneja, R. Drugs that target dynamic microtubules: a new molecular perspective. Med. Res. Rev., 2011, 31, 443-481.
12. Canta, A.; Chiorazzi, A.; Cavaletti, G. Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system. Curr. Med.Chem., 2009, 16, 1315-1324.
13. Ozcelik, B.; Kartal, M.; Orhan, I. Cytotoxicity, antiviral and antimicrobial activities of alkaloids, flavonoids, and phenolic acids. Pharm. Biol., 2011, 49, 396-402.
14. Jordan, M.A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. Anticancer Agents, 2002, 2, 1-17.
15. Landen, J.W.; Hau, V.; Wang, M.; Davis, T.; Ciliax, B.; Wainer, B.H.; Van Meir, E.G.; Glass, J.D.; Joshi, H.C.; Archer, D.R. Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin. Cancer Res., 2004, 10, 5187-5201.
16. Lechertier, T.; Hodivala-Dilke, K. Focal adhesion kinase and tumor angiogenesis. J. Pathol., 2012, 226, 404-412.
17. Newcomb, E.W.; Lukyanov, Y.; Schnee, T.; Ali, M.A.; Lan, L.; Zagzag, D. Noscapine inhibits hypoxia-mediated HIF-1α expression and angiogenesis in vitro: a novel function for an old drug. Int. J. Oncol., 2006, 28, 1121-1130.
18. Newcomb, E.W.; Lukyanov, Y.; Alonso-Basanta, M.; Esencay, M.; Smirnova, I.; Schnee, T.; Shao, Y.; Devitt, M.L.; Zagzag, D.; McBride, W.; Formenti, S.C. Antiangiogenic effects of noscapine enhance radio response for GL261 tumors. Int. J. Radiat. Oncol. Biol. Phys., 2008, 71, 1477-1484.
19. Dahlstrom, B.; Mellstrand, T.; Lofdahl, C.G.; Johansson, M. Pharmacokinetic properties of noscapine. Eur. J. Clin. Pharmacol., 1982, 22, 535-539.
20. Nayak, K.P.; Brochmann-Hanssen, E.; Way, E.L. Biological disposition of noscapine. I. Kinetics of metabolism, urinary excretion, and organ distribution. J. Pharm. Sci., 1965, 54, 191-194.
21. Verma, A.K.; Bansal, S.; Singh, J.; Tiwari, R.K.; Kasi Sankar, V.; Tandon, V.; Chandra, R. Synthesis and in vitro cytotoxicity of haloderivatives of noscapine. Bioorg. Med. Chem., 2006, 14, 6733-6736.
22. Karna, P.; Sharp, S.M.; Yates, C.; Prakash, S.; Aneja, R. EM011 activates a survivin-dependent apoptotic program in human nonsmall cell lung cancer cells. Mol. Cancer., 2009, 8, 93-105.
23. Karna, P.; Rida, P.C.; Pannu, V.; Gupta, K.K.; Dalton, W.B.; Joshi, H.; Yang, V.W.; Zhou, J.; Aneja, R. A novel microtubule-modulating noscapinoid triggers apoptosis by inducing spindle multipolarity via centrosome amplification and declustering. Cell Death Differ., 2011, 18, 632-644.
24. Aneja, R.; Miyagi, T.; Karna, P.; Ezell, T.; Shukla, D.; Vij Gupta, M.; Yates, C.; Chinni, S.R.; Zhau, H.; Chung, L.W.; Joshi, H.C. A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells. Eur. J. Cancer, 2010, 46, 1668-1678.
25. Mishra, R.C.; Karna, P.; Gundala, S.R.; Pannu, V.; Stanton, R.A.; Gupta, K.K.; Robinson, M.H.; Lopus, M.; Wilson, L.; Henary, M.; Aneja, R. Second generation benzofuranone ring substituted noscapine analogs: synthesis and biological evaluation. Biochem. Pharmacol., 2011, 82, 110-121.
26. Naik, P.K.; Chatterji, B.P.; Vangapandu, S.N.; Aneja, R.; Chandra, R.; Kanteveri, S.; Joshi, H.C. Rational design, synthesis and biological evaluations of amino-noscapine: a high affinity tubulinbinding noscapinoid. J. Comput. Aided Mol. Des., 2011, 25, 443-454.
27. Santoshi, S.; Naik, P.K.; Joshi, H.C. Rational design of novel antimicrotubule agent (9-azido-noscapine) from quantitative structure activity relationship (QSAR) evaluation of noscapinoids. J. Biomol. Screen., 2011, 16, 1047-1058.
28. Aneja, R.; Zhou, J.; Vangapandu, S.N.; Zhou, B.; Chandra, R.; Joshi, H.C. Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule agent, EM011. Blood, 2006, 107, 2486-2492.
29. Chougule, M.B.; Patel, A.R.; Jackson, T.; Singh, M. Antitumor activity of noscapine in combination with doxorubicin in triple negative breast cancer. PLoS One, 2011, 6, e17733.
30. Chougule, M.B.; Patel, A.; Sachdeva, P.; Jackson, T.; Singh, M. Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against nonsmall cell lung cancer. PLoS One, 2011, 6, e27394.
31. Pannu, V.; Karna, P.; Sajja, H.K.; Shukla, D.; Aneja, R. Synergistic antimicrotubule therapy for prostate cancer. Biochem. Pharmacol., 2011, 81, 478-487.
32. Erguven, M.; Bilir, A.; Yazihan, N.; Ermis, E.; Sabanci, A.; Aktas, E.; Aras, Y.; Alpman, V. Decreased therapeutic effects of noscapine combined with imatinib mesylate on human glioblastoma in vitro and the effect of midkine. Cancer Cell Int., 2011, 11, 18.
33. Barreto, J.A.; Malley, W.O.; Kubeil, M.; Graham, B.; Stephan, H.; Spiccia, L. Nanomaterials: applications in cancer imaging and therapy. Advanced Materials, 2011, 23, H18-H-40.
34. Irache, J.M.; Esparza, I.; Gamazo, C.; Agüeros, M.; Espuelas, S. Nanomedicine: novel approaches in human and veterinary therapeutics. Vet. Parasitol., 2011, 180, 47-71.
35. Zhao, F.; Zhao, Y.; Liu, Y.; Chang, X.; Chen, C.; Zhao, Y. Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. Small, 2011, 7, 1322-1337.
36. Chidambaram, M.; Manavalan, R.; Kathiresan, K. Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J. Pharm. Pharm. Sci., 2011, 14, 67-77.
37. Zhang, J.; Lan, Q.C.; Post, M.; Simard, B.; Deslandes, Y.; Heiseh, H.T. Design of nanoparticles as drug carrier for cancer therapy. A review: Cancer Genom. Proteo., 2006, 3, 147-158.
38. Smith, J. Beaker, a medical research blog by Sanford-Burnham, Medical Reserch Institute, Lajulla California USA. www.sanfordburnham.org
39. Alexiou, C.; Arnold, W.; Klein, R.J.; Parak, F.G.; Hulin, P.; Bergemann, C.; Erhardt, W.; Wagenpfeil, S.; Lubbe, A.S.; Locoregional cancer treatment with magnetic drug targeting. Cancer Res., 2000, 60, 6641-6648.
40. Lubbe, A.S.; Bergemann, C.; Brock, J.; McClure, D.G. Physiological aspects in magnetic drug-targeting. J. Mag. Magnetic Mater., 1999, 194, 149-155.
41. Novakova, A.A.; Lanchinskaya, V.Y.; Volkov, A.V.; Gendler, T.S.; Kiseleva, T.Y.; Moskvina, M.A.; Zezin, S.B. Magnetic properties of polymer nanocomposites containing iron oxide nanoparticles. J. Mag. Magnetic Mater., 2003, 258-259, 354-357.
42. Dandamudi, S.; Campbell, R.B. The drug loading cytotoxicity and tumor vascular targeting characteristics of magnetite in magnetic drug targeting. Biomaterials, 2007, 28, 4673-4683.
43. Yoo, J.W. Toward improved selectivity of targeted delivery: The potential of magnetic nanoparticles. Arch. Pharm. Res., 2012, 35, 1-2.
44. Hu, F.X.; Neoh, K.G.; Kang, E.T. Synthesis and in vitro anticancer evaluation of tamoxifen-loaded magnetite/PLLA composite enanocomposites. Biomaterials, 2006, 27, 5725-5733.
45. Fonseca, C.; Simoes, S.; Gasper, R. Paclitaxel-loaded PLGA nanoparticles: preparation, physiochemical characterization and in vitro anti-tumoral activity. J. Control. Rel., 2002, 83, 273-286.
46. Joshi, H.C.; Zhou, J. Noscapine and analogues as potential chemotherapeutic agents. Drug News Perspect., 2000, 13, 543-546.
47. Zhang, A.; Anyarambhatla, G.; Ma, L.; Ugwu, S.; Xuan, T.; Sardone, T.; Ahmad, I. Development and characterization of a novel cremophor EL free liposome based paclitaxel (LEP-ETU) formulation. Eur. J. Pharm. Biopharm., 2005, 59, 177-187.
48. Liu, Yu.; Chen, G.S.; Chen, Y.; Cao, D.X.; Ge, Z.Q.; Yuan, Y.J. Inclusion complex of paclitaxel and oligo (ethylenediamino) bridged bis (β-cyclodextrin)s: solubilization and antitumor activity. Bioorg. Med. Chem., 2004, 12, 5767-5775.
49. Abdalla, M.O.; Karna, P.; Sajja, H.K.; Mao, H.; Yates, C.; Turner, T.; Aneja, R. Enhanced noscapine delivery using μPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy. J. Control. Release, 2011, 149, 314-322.
50. Sebak, S.; Mirzaei, M.; Malhotra, M.; Kulamarva, A.; Prakash, S. Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis. Int. J. Nanomed., 2010, 5, 525-532